GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings.Key metrics for WGS include test volume growth and reimbursement rates, with management targeting a 30% annual volume increase and improving price realization.Consensus-beating revenue is likely if test volume growth accelerates and pricing im...
follow.it gives you an easy way to subscribe to Prudent Biotech's news feed! Click on Follow below and we deliver the updates you want via email, phone or you can read them here on the website on your own news page.
You can also unsubscribe anytime painlessly. You can even combine feeds from Prudent Biotech with other site's feeds!
Title: Prudent Biotech – Building Incredible Wealth in Biotechs Over Time with Prudence, Patience, and Performance